Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z0GX
|
||||
| Former ID |
DIB007880
|
||||
| Drug Name |
SUVN-502
|
||||
| Synonyms |
SVN-502; 5-HT 6 receptor antagonist (Alzheimer's disease), Suven; 5-HT 6 receptor antagonist (cognitive/memory disorder), Suven
|
||||
| Indication | Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10:I21, I22, R52, R52.1-R52.2, R60.9, G89] | Phase 2 | [1] | ||
| Company |
Suven Life Sciences
|
||||
| Structure |
|
Download2D MOL |
|||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 6 receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Serotonergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| PathWhiz Pathway | Excitatory Neural Signalling Through 5-HTR 6 and Serotonin | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (s) signalling events | |||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Clinical pipeline report, company report or official report of Suven Life Sciences. | ||||
| REF 2 | Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.